Investigational Site Number :1240001

Montreal, Quebec H4A 3J1

2 studies enrolling now · 11 studies all time

What they study most

Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis Without Nasal Polyps, Chronic Sinusitis, Chronic Spontaneous Urticaria, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Hemophilia, Parkinson's Disease, Plasma Cell Myeloma, Plasma Cell Myeloma Refractory, Respiratory Disorder, Sinus Disorder

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease — Recruiting now
• A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma — Recruiting now
• Dupilumab in CRSsNP — Completed
• Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX — Running, not enrolling
• Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma — Running, not enrolling
• A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids) — Completed
• A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204) — Stopped early
• Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients — Completed
• Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients — Completed
• Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation — Completed
• A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation — Stopped early